Janet Woodcock to Serve as Acting Commissioner of FDA
Woodcock will serve as acting commissioner of FDA, taking over for Stephen Hahn, FDA’s previous acting commissioner.
On Jan. 20, 2021, Janet Woodcock, MD announced in a note to FDA staff members that she will serve as acting commissioner of FDA, taking over for Stephen Hahn, FDA’s previous acting commissioner.
Woodcock joined FDA in 1986 and has held several positions, including deputy commissioner and chief medical officer, deputy commissioner for operations, chief operating officer for the commissioner’s office, and director of the Center for Drug Evaluation and Research (CDER).
“I know you all have endured hardships while carrying out our public health mission, balancing work and family, and trying to stay safe. It has not gone unnoticed,” she wrote in her note. “I believe life will improve in 2021, but I don’t know how quickly that will happen. The hope keeps me going. I look forward to working with you to achieve our vital public health mission, and with our HHS [Department of Health and Human Services] partners and The White House during this transitional period.”
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
